Tempest Therapeutics jumps after-hours on Hebei Senlang option deal
Tempest Therapeutics (TPST) rose about 66% after-hours to $1.26 following an exclusive option deal with Hebei Senlang. The company said its dose-escalation trial showed no Grade 3+ cytokine release syndrome or ICANS as of Aug 25.